We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Researchers in China say that no side effects have been observed during the world's first human trials of a vaccine against severe acute respiratory syndrome (SARS). Thirty-six volunteers received either low or high doses of the vaccine. The first group has completed the trial while the second has received one of two doses.

If China's State Drug Administration approves the results, the researchers will proceed with the second phase of trials. But health officials in China say full development and mass production of a SARS vaccine are still years away.

The research was conducted by Sinovac Biotech Ltd in China, where SARS first emerged in 2003 before spreading to 32 countries and killing about 800 people.

Link to full ABC News Online news story

Related topics